Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Completed · Phase 3

Conditions studied: Hereditary Angioedema

In brief

KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.

Key facts

Study ID

NCT06467084

Run by

KalVista Pharmaceuticals, Ltd.

People needed

36

Starts

2024-08-01

Expected to finish

2026-01-15

Last updated by the study team

2026-08-05

Who can join

Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients 2 to 11 years of age.
• Confirmed diagnosis of HAE Type I or II.
• For patients ≥20 kg at screening, patient has had at least 1 documented HAE attack in the last year prior to screening.
• Caregiver, as assessed by the Investigator, must be able to appropriately store and administer IMP and be able to read, understand, and complete the diary.
• Investigator believes that the patient and caregiver are willing and able to adhere to all protocol requirements.
• Parent or Legally Authorized Representative (LAR) provides signed informed consent and patient provides assent (when applicable).

You may not qualify if…

• Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH, idiopathic angioedema, or angioedema associated with urticaria.
• A clinically significant history of poor response to bradykinin receptor 2 blocker, C1-INH therapy, or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
• Patient weighs <9.5 kg.
• Use of angiotensin-converting enzyme inhibitors after the Screening Visit.
• Any estrogen-containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit.
• Patients who require sustained use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers or moderate CYP3A4 inducers.
• Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial.
• Known hypersensitivity to sebetralstat or to any of the excipients.
• Participation in any interventional investigational clinical trial within 4 weeks of the last dosing of investigational drug prior to the Screening Visit.

Where it is running

• KalVista Investigative Site — Birmingham, Alabama, United States
• KalVista Investigative Site — Scottsdale, Arizona, United States
• KalVista Investigative Site — San Diego, California, United States
• KalVista Investigative Site — Santa Monica, California, United States
• KalVista Investigative Site — Evansville, Indiana, United States
• KalVista Investigative Site — Wheaton, Maryland, United States
• KalVista Investigative Site — St Louis, Missouri, United States
• KalVista Investigative Site — Toledo, Ohio, United States
• KalVista Investigative Site — Hershey, Pennsylvania, United States
• KalVista Investigative Site — Dallas, Texas, United States
• KalVista Investigative Site — Edmonton, Alberta, Canada
• KalVista Investigative Site — Lille, France
• KalVista Investigative Site — Marseille, France
• KalVista Investigative Site — Paris, France
• KalVista Investigative Site — Frankfurt am Main, Germany
• KalVista Investigative Site — Frankfurt am Main, Germany
• KalVista Investigative Site — Haifa, Israel
• KalVista Investigative Site — Petah Tikva, Israel
• KalVista Investigative Site — Tel Aviv, Israel
• KalVista Investigative Site — Milan, Italy
• KalVista Investigative Site — Padova, Italy
• KalVista Investigative Site — Rome, Italy
• KalVista Investigative Site — Kawagoe, Japan
• KalVista Investigative Site — Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.